Greenlight Ventures, LLC Takes a Stake in Nexalin Technology, Inc.
In an intriguing move within the tech and health landscape, Greenlight Ventures, LLC has disclosed a 5.6% stake in the common stock of Nexalin Technology, Inc. This revelation was made public through an official filing on September 3, 2026, marking a significant milestone in both companies’ ongoing collaboration.
The Nature of the Deal
The acquisition of this stake came as part of a larger transaction where Greenlight received stock as non-cash consideration for Nexalin’s purchase of PONM. This strategic partnership not only deepens financial ties between the two entities but also establishes a framework for continued collaboration, allowing Greenlight to provide essential technical and strategic support to Nexalin. It represents a mutual commitment to advancing innovative technologies in the digital health sector.
Future Financial Considerations
Greenlight Ventures is set to receive two remaining stock tranches that are tied to the $1.3 million purchase price of PONM, expected to be finalized around November 10, 2026, and February 8, 2027. The shares will be issued at a predetermined reference price, offering certain anti-dilution protections, which are crucial for maintaining the value of their investment. Additionally, in the event of a change of control at Nexalin, all remaining unissued consideration shares will become issuable immediately, providing an added layer of security for Greenlight.
Governance and Control
While Greenlight holds a minority interest in Nexalin, it’s crucial to highlight that the firm does not possess any governance rights. According to the filing, Greenlight has no authority to designate or nominate members to Nexalin’s board of directors. Notably, David Owens, a director at Nexalin and its Chief Medical Officer, holds only a minority interest in Greenlight. This delineation of control is significant, as it clarifies the operational dynamics between the two companies and emphasizes that financial investment does not equate to managerial influence.
Collaboration Agreement
In addition to its equity stake, Greenlight Ventures has entered into a separate collaboration agreement, which stipulates a monthly payment of $10,000 for product development support. This financial arrangement is tailored to foster product innovation without influencing voting rights or share disposition arrangements. Such delineation ensures a focused partnership geared towards technological development, free from governance-related distractions.
About Greenlight Ventures
Greenlight Ventures, LLC is based in North Carolina and focuses on developing and licensing software and platform technologies specifically for digital health applications. By partnering with medical technology companies, Greenlight aims to scale software-enabled products and compliance systems, driving innovation in the health sector. The firm is led by member Peter Gratale, whose leadership has been pivotal in navigating these recent developments.
The Broader Context
The investment by Greenlight Ventures highlights the growing intersection between technology and healthcare. As digital health solutions become increasingly vital in today’s healthcare environment, partnerships such as the one between Greenlight and Nexalin could pave the way for groundbreaking innovations. For industry observers and investors alike, this transaction may signal more strategic alignments as companies seek to leverage technology to enhance patient care and operational efficiencies.
Official Filing and Resources
For those interested in exploring the details of this transaction further, the original SEC filing can be accessed through the following link: Nexalin Technology, Inc. – SCHEDULE 13D – Sep. 03, 2026. This document provides granular insights into the financial and governance structures established through this partnership, offering a comprehensive view of implications for both companies.
